Ingo K. Mellinghoff - Publications, H-index & Citations

Ingo K. Mellinghoff

memorial sloan kettering cancer center

79H指数

615论文数

3.8W被引数

收录论文 169

发表时间

Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial 新辅助PD1联合CTLA-4免疫检查点阻断在可手术切除的复发性胶质母细胞瘤中的应用：一项随机手术窗口期试验

Nature Communications

IF15.7

2026-09-05

OAAI

Lu Sun; Lauren F. Markus; Julio C. Sanchez; Thomas J. Lai; Eudocia Quant Lee; Gang Li; Jiyoon Kim; Zian Zhuang; Brenda Acevedo; Richard G. Everson; Ingo K. Mellinghoff; Elisa Aquilanti; L. Nicolas Gonzalez Castro; J. Ricardo McFaline-Figueroa; Lakshmi Nayak; Rameen Beroukhim; Robert A. Chong; Jacqueline Stone; Thomas Kaley; Lauren Schaff; Jessica Wilcox; Catharina Westergaard; Alyssa Russ; Maria Lavallee; Ugonma Chukwueke; Annick D. Van den Abbeele; Michael Lim; Benjamin M. Ellingson; David A. Reardon; Timothy F. Cloughesy; Robert M. Prins; Patrick Y. Wen

Primitive neuronal component is a frequent finding among IDH-mutant astrocytomas with RB1 alterations IDH突变伴RB1改变的星形细胞瘤中常见原始神经元成分

Acta Neuropathologica

IF9.3

2026-04-19

OAAI

Cheyanne C. Slocum; Jamal K. Benhamida; Scott Eckert; Erika Gedvilaite; Ryan Ptashkin; Viviane Tabar; Robert J. Young; Marc Ladanyi; Ingo K. Mellinghoff; Marc K. Rosenblum; A. Rose Brannon; Richard Hickman; Tejus A. Bale

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma 伊布替尼联合利妥昔单抗、甲氨蝶呤、长春新碱和丙卡巴肼治疗新诊断的原发性中枢神经系统淋巴瘤

Neuro-Oncology

IF13.4

2026-03-01

PREAI

Schaff, Lauren R.; Pentsova, Elena; Malani, Rachna; Stone, Jacqueline; Gavrilovic, Igor T.; Kaley, Thomas J.; Emadi-Paramkouhi, Laleh; Yang, Kerina; Gonzalez, Ashley; Quinn, Lilian; Rodriguez, Alyssa; Tobin, Josey; Kaluski, Maya; Reiner, Anne S.; Panageas, Katherine S.; Deangelis, Lisa M.; Francis, Jasmine H.; Young, Robert J.; Mellinghoff, Ingo K.; Grommes, Christian

Outcomes of inpatient chemoradiotherapy for patients with newly diagnosed glioblastoma and significant functional impairment 新诊断胶质母细胞瘤伴显著功能损害患者住院化放疗的结局

Neuro-Oncology Practice

IF2.5

2026-01-01

OAAI

Sielski, Neil; Reiner, Anne S.; Rosa, William E.; Imber, Brandon S.; Pike, Luke R. G.; Voigt, Louis P.; Schaff, Lauren R.; Lin, Andrew L.; Grommes, Christian; Gavrilovic, Igor T.; Stone, Jacqueline; Carver, Alan C.; Rosenblum, Marc; Tabar, Viviane; Kaley, Thomas; Mellinghoff, Ingo K.; Pentsova, Elena

CTIM-12. DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES CTIM-12. 双免疫检查点阻断治疗可手术切除的复发性胶质母细胞瘤：临床与分子结局

Neuro-Oncology

IF13.4

2025-11-11

OAAI

Lu Sun; Eudocia Quant Lee; Gang Li; David A Reardon; Brenda Acevedo; Catharina Westergaard; Alyssa Russ; Richard G Everson; Benjamin M Ellingson; Ingo K Mellinghoff; Elisa Aquilanti; L Nicolas Gonzalez Castro; J Ricardo McFaline-Figueroa; Lakshmi Nayak; Rameen Beroukhim; Robert A Chong; Jacqueline Stone; Thomas Kaley; Lauren Schaff; Jessica wilcox; Maria Lavallee; Ugonma Chukwueke; Annick D Van den Abbeele; Michael Lim; Timothy F Cloughesy; Robert M Prins; Patrick Y Wen

CTNI-53. PATIENTS WITH ISOCITRATE DEHYDROGENASE-MUTANT GLIOMA TREATED WITH VORASIDENIB: UPDATED DATA FROM THE VORASIDENIB EXPANDED ACCESS PROGRAM CTNI-53. 接受vorasidenib治疗的异柠檬酸脱氢酶突变型胶质瘤患者：来自vorasidenib扩展性用药项目的更新数据

Neuro-Oncology

IF13.4

2025-11-11

OAAI

Timothy F Cloughesy; Katherine B Peters; Howard Colman; Jennie W Taylor; Ingo K Mellinghoff; Helen A Shih; Christelle Chacar; Jonathan Dewey; Patrick Y Wen

Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial 与接受vorasidenib或安慰剂治疗的Grade 2，异柠檬酸脱氢酶1/2突变（mIDH1/2）胶质瘤患者中，体素（3D）评估相较于传统双向（2D）评估在INDIGO III期试验中的比较

NEURO-ONCOLOGY

IF13.4

2025-11-01

OAAI

Ellingson, Benjamin M.; Mellinghoff, Ingo; Van Den Bent, Martin J.; Blumenthal, Deborah T.; Touat, Mehdi; Peters, Katherine B.; Clarke, Jennifer L.; Mendez, Joe; Yust-Katz, Shlomit; Welsh, Liam; Mason, Warren P.; Ducray, Francois; Umemura, Yoshie; Nabors, Burt; Holdhoff, Matthias; Hottinger, Andreas F.; Arakawa, Yoshiki; Sepulveda, Juan M.; Wick, Wolfgang; Soffietti, Riccardo; Perry, James; Giglio, Pierre; De La Fuente, Macarena, I; Maher, Elizabeth; Zhao, Dan; Pandya, Shuchi S.; Steelman, Lori; Hassan, Islam; Wen, Patrick Y.; Cloughesy, Timothy F.

PHASE 1B SAFETY RESULTS OF VORASIDENIB IN COMBINATION WITH TEMOZOLOMIDE IN PATIENTS WITH MUTANT IDH1 OR IDH2 GLIOMA 1B期试验中，vorasidenib与temozolomide联合治疗携带IDH1或IDH2突变的胶质瘤患者的安全性结果。

NEURO-ONCOLOGY

IF13.4

2025-11-01

OAAI

de la Fuente, Macarena, I; Cloughesy, Timothy F.; Touat, Mehdi; Lopez, Juanita; McBain, Catherine; Steelman, Lori; Hassan, Islam; Jain, Payal; Man, Albert; Abshire, Michelle; Knipstein, Jeffrey; Mellinghoff, Ingo; Wen, Patrick Y.

PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) IN PATIENTS WITH CNS LYMPHOMA 计划用于门诊高剂量甲氨蝶呤（HD-MTX）治疗中枢神经系统淋巴瘤患者的葡糖醛酸酶。

NEURO-ONCOLOGY

IF13.4

2025-11-01

OAAI

Schaff, Lauren; Lobbous, Mina; Schofield, Ryan; Carlow, Dean; Gonzalez, Ashley; Emadi-Paramkouhi, Laleh; Kahleifeh, Adam; Reiner, Anne; Panageas, Katherine; Nabors, Louis B.; Deangelis, Lisa; Mellinghoff, Ingo; Grommes, Christian

PLANNED GLUCARPIDASE FOR CNS LYMPHOMA PATIENTS AT HIGH RISK OF METHOTREXATE (MTX) TOXICITY 计划为高风险甲氨蝶呤（MTX）毒性中枢神经系统淋巴瘤患者使用葡萄糖醛酸酶。

NEURO-ONCOLOGY

IF13.4

2025-11-01

OAAI

Schaff, Lauren; Lobbous, Mina; Kahleifeh, Adam; Schofield, Ryan; Carlow, Dean; Reiner, Anne; Panageas, Katherine; Nabors, Louis B.; Deangelis, Lisa; Mellinghoff, Ingo; Grommes, Christian

LU-TARGET: A Phase 1 Study of Lutetium-177-PSMA-617 Adjuvant Radiotherapy for IDH wild type Gliomas Expressing PSMA following standard Treatment LU-TARGET：一项关于177Lu-PSMA-617辅助放射治疗标准治疗后表达PSMA的IDH野生型胶质瘤的1期研究

NEURO-ONCOLOGY

IF13.4

2025-11-01

OAAI

Imber, Brandon; Jackson, Christopher; Young, Robert; Humm, John; Grkovski, Milan; Bale, Tejus; Miller, Alexandra; Mellinghoff, Ingo; Krebs, Simone; Schoder, Heiko; Kaley, Thomas

SELINEXOR FOR THE TREATMENT OF GLIOMA: A RETROSPECTIVE CASE SERIES 塞利尼索用于胶质瘤治疗：一项回顾性病例系列研究

NEURO-ONCOLOGY

IF13.4

2025-11-01

OAAI

Lee, Edward; Miller, Alexandra; Lin, Andrew; Budhu, Joshua; Wilcox, Jessica; Diamond, Eli; Kahleifeh, Adam; Mellinghoff, Ingo; Schaff, Lauren

PHASE IB STUDY OF COPANLISIB, A PAN PI3K INHIBITOR, IN COMBINATION WITH IBRUTINIB, A BTK INHIBITOR, IN RELAPSED OR REFRACTORY PRIMARY CNS LYMPHOMA I期B研究：评估泛PI3K抑制剂copanlisib与BTK抑制剂ibrutinib联合治疗复发或难治性原发性中枢神经系统淋巴瘤的疗效。

NEURO-ONCOLOGY

IF13.4

2025-11-01

OAAI

Schaff, Lauren; Gavrilovic, Igor; Stone, Jacqueline; Piotrowski, Anna; Nayak, Lakshmi; Malani, Rachna; Miller, Alexandra; Modelevsky, Lisa; Hatzoglou, Vaios; Young, Robert; DeAngelis, Lisa; Reiner, Anne; Panageas, Katherine; Francis, Jasmin; Mellinghoff, Ingo; Grommes, Christian

Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma GBM AGILE更新：一项全球性、II/III期自适应平台试验，旨在评估新诊断和复发性胶质母细胞瘤中的多种治疗方案

NEURO-ONCOLOGY

IF13.4

2025-11-01

OAAI

Lim, Michael; Berry, Donald; Berry, Nicholas; Colman, Howard; De Groot, John; Ellingson, Benjamin; Gan, Hui; Hyddmark, E. Viktoria; Johnson, Adam; Lassman, Andrew; Mellinghoff, Ingo; Perry, James; Sulman, Erik; Weller, Michael; Wen, Patrick; Cloughesy, Timothy; Network, Gbm Agile Trial

Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial 体积肿瘤生长率（TGR）建模预测了在INDIGO三期试验中，接受vorasidenib或安慰剂治疗的Grade 2、异柠檬酸脱氢酶1/2突变（mIDH1/2）胶质瘤患者的临床结局。

NEURO-ONCOLOGY

IF13.4

2025-11-01

OAAI

Glioblastoma distant recurrences preferentially occur along white matter tracts mapped using probabilistic diffusion tractography 胶质母细胞瘤的远处复发倾向于沿着使用概率性扩散纤维追踪技术绘制的白质束发生。

NEURO-ONCOLOGY

IF13.4

2025-11-01

OAAI

Gui, Chengcheng; Jenabi, Mehrnaz; Brennan, Cameron; Moss, Nelson; Yu, Kenny; Nassif, Rabih Bou; Tabar, Viviane; Kaley, Thomas; Pike, Luke; Stember, Joseph; Young, Robert; Pasquini, Luca; Peck, Kyung; Mellinghoff, Ingo; Imber, Brandon; Holodny, Andrei

IBRUTINIB IN COMBINATION WITH RITUXIMAB, METHOTREXATE (MTX), VINCRISTINE, AND PROCARBAZINE (R-MPV/I) FOR NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (PCNSL)伊布替尼联合利妥昔单抗、甲氨蝶呤（MTX）、长春新碱和丙卡巴肼（R-MPV/I）用于新诊断的原发性中枢神经系统淋巴瘤（PCNSL）

NEURO-ONCOLOGY

IF13.4

2025-11-01

OAAI

Schaff, Lauren; Pentsova, Elena; Malani, Rachna; Stone, Jacqueline; Gavrilovic, Igor; Emadi-Paramkouhi, Laleh; Kaluski, Maya; Reiner, Anneq; Panageas, Katherine; Francis, Jasmine; Young, Robert; Mellinghoff, Ingo; Grommes, Christian

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial Vorasidenib在IDH1突变或IDH2突变低级别胶质瘤（INDIGO）：一项随机、双盲、安慰剂对照、III期试验的次要和探索性终点

The Lancet Oncology

IF0

2025-10-29

PREAI

Timothy F Cloughesy; Martin J van den Bent; Mehdi Touat; Deborah T Blumenthal; Katherine B Peters; Benjamin M Ellingson; Jennifer L Clarke; Joe Mendez; Shlomit Yust-Katz; Liam Welsh; Warren P Mason; Francois Ducray; Yoshie Umemura; Burt Nabors; Matthias Holdhoff; Andreas F Hottinger; Yoshiki Arakawa; Juan M Sepulveda; Wolfgang Wick; Riccardo Soffietti; James Perry; Pierre Giglio; Macarena de la Fuente; Elizabeth Maher; Andrew Bottomley; Adriana E Tron; Denise Yi; Dan Zhao; Shuchi S Pandya; Lori Steelman; Islam Hassan; Patrick Y Wen; Ingo K Mellinghoff

EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL 早期肿瘤体积变化预测Midh1/2胶质瘤的临床结局：INDIGO III期试验的事后分析结果

NEURO-ONCOLOGY

IF13.4

2025-10-01

OAAI

Ellingson, B. M.; Mellinghoff, I. K.; van den Bent, M. J.; Blumenthal, D. T.; Touat, M.; Peters, K. B.; Clarke, J. L.; Mendez, J.; Yust-Katz, S.; Welsh, L.; Mason, W. P.; Ducray, F.; Umemura, Y.; Nabors, B.; Holdhoff, M.; Hottinger, A. F.; Arakawa, Y.; Sepulveda, J. M.; Wick, W.; Soffietti, R.; Perry, J.; Giglio, P.; de la Fuente, M.; Maher, E.; Zhao, D.; Pandya, S. S.; Steelman, L.; Hassan, I; Wen, P. Y.; Cloughesy, T. F.

EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB 来自INDIGO研究第3阶段的探索性分析表明，在VORASIDENIB治疗下，通过肿瘤体积减小可能存在控制癫痫发作的潜在机制。

NEURO-ONCOLOGY

IF13.4

2025-10-01

OAAI

Wick, W.; Mellinghoff, I. K.; van den Bent, M. J.; Blumenthal, D. T.; Touat, M.; Peters, K. B.; Clarke, J. L.; Mendez, J.; Welsh, L.; Mason, W. P.; Hottinger, A. F.; Sepulveda, J. M.; Soffietti, R.; Zhao, D.; Yi, D.; Weidl, D.; Steelman, L.; Hassan, I; Wen, P. Y.; Cloughesy, T. F.

研究方向